Proactive Investors - Run By Investors For Investors

Cellmid director shows faith in life sciences company through on-market trades

Bruce Gordon has acquired two batches of shares recently with a total value of almost $13,300.
Australian currency
The company has lead programs in multiple disease indications

Cellmid Limited (ASX:CDY) non-executive director Bruce Gordon continues to demonstrate his confidence in the life sciences company through on-market share purchases.

Gordon has acquired a further 8,684 shares valued at almost $3,300 and now holds 110,000 shares in an indirect interest.

Last week’s acquisition follows a recent purchase of more than 26,000 shares valued at $10,000.

READ: Cellmid gains new substantial shareholder as director increases his interest to 6.4%

Other company directors have also been acquiring shares recently in a variety of ways, including on-market trades and participation in the recent share placement and share purchase plan.
US-based non-executive director Dennis Eck is a substantial shareholder with a 6.4% interest after acquiring a further batch of shares valued at $1 million.

Managing director and CEO Maria Halasz acquired shares valued at $100,000 while non-executive director Dr Martin Cross has made purchases valued at $50,400.

READ: Cellmid driving towards profitability with anti-ageing product range

Cellmid is an Australian life sciences accelerator with lead programs in multiple disease indications.

The company holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. 

Cellmid, through wholly-owned subsidiaries Lyramid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart and hair loss.

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

pills
November 08 2018
'I joke that Wall Street and Big Pharma didn't wake up today wondering where that next $10 million Canadian product is going to come from, but we do,' says CEO Doug Janzen
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use